Adjuvant biologic therapy for breast cancer.
Breast cancer continues to be a major health problem despite a decrease in mortality rates over the past 2 decades. Although many advances have been made in the treatment of breast cancer, drug therapy for the disease continues to evolve as more is learned about cell biology and cellular signaling pathways. The development of targeted agents offers the hope of new therapies with better efficacy and tolerability. Biologic therapy has been a cornerstone of targeted therapy for the treatment of advanced breast cancer and is now entering the adjuvant arena. This review summarizes the results of several adjuvant studies and discusses future directions for breast cancer biotherapy.
Craft
Barbara S
BS
Division of Hematology and Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
Hortobagyi
Gabriel N
GN
Moulder
Stacy L
SL
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D024221:Antineoplastic Protocols; D000068258:Bevacizumab; D001691:Biological Therapy / Q000009:adverse effects / Q000379:methods*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods*; D004815:Epidermal Growth Factor / Q000187:drug effects; D066246:ErbB Receptors / Q000187:drug effects; D005260:Female; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D000068878:Trastuzumab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D004815:Epidermal Growth Factor; C512478:EGFR protein, human; D066246:ErbB Receptors; D000068878:Trastuzumab